Get hired at Hiring now
iPremom
A first-trimester blood test that predicts preeclampsia months before symptoms
- —
- ACPAPAV
- Paterna
- AI
Open roles at iPremom
4 positions we're tracking, re-checked daily
- Apply ↗
Regulatory Affairs Lead (IVDR / FDA submissions)
Paterna, Valencia, SpainSeniorFirst seen last month - Apply ↗
Clinical Operations Manager (multicentre validation studies)
Paterna, Valencia, SpainMid-levelFirst seen last month - Apply ↗
Bioinformatics Scientist (cfRNA signal processing and predictive modelling)
Paterna, Valencia, SpainMid-levelFirst seen last month - Apply ↗
Commercial Lead — EU market access
Paterna, Valencia, SpainSeniorFirst seen last month
Tracking iPremom
Last checked October 18, 2026Know when iPremom is hiring before anyone else
A role stays uncontested for about four days. Here's the window, and where we put you in it.
- Live
- +2h+2hRole spotted & verified1 applicant
- +4h+4hYou get the alert1 applicant
- Day 3Day 3You've applied~8 applicants
- Day 7+Day 7+Hits the job boards250+ applicants
The product
What iPremom is building
MaiRa is a blood test that reads cell-free RNA in maternal circulation from as early as week 9 of pregnancy and returns a risk assessment for preeclampsia, pre-term birth, foetal growth restriction and gestational diabetes. One draw, first trimester, months before any clinical sign appears. The company describes it as the first test able to assess preeclampsia risk from week 9. The biology underneath is the reason this is a company rather than a screening tweak. Dr Garrido's work, published in Nature Medicine, characterises decidualisation resistance: a failure of the endometrium to prepare properly for implantation and placental development. Using digital tissue analysis, single-cell sequencing and spatial biology, the study found altered glandular morphology in the endometrial tissue of preeclampsia patients, with proliferative-phenotype cells coexisting alongside the expected decidualised phenotype. In other words, the signal that predicts a third-trimester catastrophe is present in the uterine lining before the pregnancy even establishes. MaiRa turns that into a cfRNA signature and a predictive model over a single blood sample. The validation set is the unusual asset here: the PREMOM consortium recruited more than 9,500 pregnant women across 14 Spanish hospitals prospectively, producing 26,000+ samples from 10,000 pregnancies. Prospective multicentre cohorts of that size are years of work and are not something a competitor assembles quickly. CEO Guillermo Ferrando frames the ambition past the single indication: 'Our ambition is not just to build a better preeclampsia test, it is to give every pregnant woman a comprehensive, early molecular picture of her pregnancy.'
The money
Why this matters
Preeclampsia is one of the leading causes of maternal and foetal morbidity worldwide, and the standard of care is still largely reactive: monitor blood pressure and proteinuria, then intervene once the condition declares itself. Low-dose aspirin prophylaxis works, but it works best when started early in the first trimester, which means the clinical value of a test is almost entirely a function of how early it reads. A week-9 molecular signal is upstream of where current risk stratification operates. The strategic argument is that this is a platform question disguised as a test. cfRNA from maternal blood is a general-purpose window into the placenta and the endometrium, and iPremom is already claiming four indications off one draw. The company has been running since 2019 and only raised its seed now, which tells you the round is priced against evidence rather than a thesis. That is a different risk profile from most seed-stage diagnostics.
Investors: Amadeus Capital Partners (lead), Asabys Partners, APEX Ventures
The outlook
Hiring outlook
The use of funds is explicit and headcount-hungry — completing clinical validation studies, pursuing regulatory approval in both the EU and US, and commercial rollout beyond the single Spanish laboratory MaiRa runs in today. That work does not happen without regulatory affairs, clinical operations and commercial hires. But there is no careers page live at ipremom.com and no stated hiring numbers, so this is implied rather than announced.
Working at iPremom
iPremom is a AI company based in Paterna, Valencia, Spain. For a AI company this size, the reality is opportunity to shape your role based on the company stage.
Most iPremom jobs are based in Paterna, Valencia, Spain.
How to actually get hired at iPremom
Why applying the normal way doesn't work
iPremom uses an ATS, but referrals still come first. Cold applications aren't ignored — they're just behind referrals, sourced candidates, and recruiter picks.
Who to contact at iPremom
- Who decides
- the hiring manager
- Best channel
- LinkedIn or direct email
What to show them
Take a public cfRNA or maternal plasma transcriptomics dataset and build an honest predictive model for an adverse pregnancy outcome. The point is not AUC. The point is how you handle a low base rate, how you avoid leaking batch or site effects in a multicentre cohort, and how you decide a threshold when a false negative is a clinical event and a false positive is an anxious patient. Show the calibration curve, not just the ROC.
A cold email that works at iPremom
What iPremom screens for
Amadeus Capital leading with Asabys and APEX alongside is a deep-tech-plus-healthcare syndicate rather than a consumer femtech one, and the size of a €15M seed for a 2019-founded company says the investors are buying validated evidence, not optionality. The hiring window is defined by the regulatory calendar: the company has to run EU and US approval processes in parallel while completing validation studies, and those teams are being assembled now. For a bioinformatician, the draw is a prospective multicentre dataset of 26,000+ samples that almost nobody else can access. For a regulatory or market-access person, this is the rare chance to own a first-in-class IVD submission from the start rather than inherit one mid-flight.
Don't send a generic CV to iPremom. Mirror the job posting's language to get past automated screening.
Avoid
Don't make these mistakes
Carlos Simón is a professor with fifteen active patents who already founded and built Igenomix, and Tamara Garrido has spent her career on endometrial decidualisation with a Nature Medicine paper behind this product. Do not explain the maternal health market to them, and do not pitch AI as the interesting part — the model is downstream of a decade of wet-lab biology and a 9,500-woman prospective cohort, and they know exactly which of those is the moat. Generic femtech enthusiasm will read as someone who has not read the science. If you are technical, engage with the cfRNA signal and the class-imbalance problem in predicting a condition with low base rates. If you are commercial, engage with reimbursement and IVDR, because that is what actually stands between MaiRa and volume.
Mistakes that kill iPremom applications
At people, a copy-paste CV is immediately obvious. It's an instant no.
Lead with their problem, not your ambition. iPremom is focused on Preeclampsia is one of the leading causes of maternal and foetal morbidity worldwide, and the standard of care is still largely reactive: monitor blood pressure and proteinuria, then intervene once the condition declares itself — show you understand that.
Don't apply and wait. The median AI application gets no response ever. One follow-up at day five roughly doubles reply rates.
Tracking iPremom
Applying to iPremom? Get the contact, not the form.
The iPremom interview process
4 stages over about 14 days, including a take-home task. See each stage, what it tests and how to prepare.
iPremom jobs, frequently asked questions
How many jobs does iPremom have open?
iPremom currently has 4 open roles, last verified October 18, 2026.
Does iPremom hire remotely?
All current iPremom roles are based in Paterna, Valencia, Spain.
What roles is iPremom hiring for?
iPremom is hiring across Data, Operations, Marketing. The most recent opening is Regulatory Affairs Lead (IVDR / FDA submissions).
How do I apply for a job at iPremom?
Apply directly through the links above, or read our guide on how to actually get hired at iPremom.
Does iPremom respond to cold emails?
We're still collecting cold email data for iPremom.
Who is the hiring manager at iPremom?
At this size, hiring is usually run by the hiring manager.
How competitive is it to get hired at iPremom?
Expect 100-250 applicants in the first two weeks for AI roles at this size. Apply within 72 hours for best odds.
Where is iPremom based?
iPremom is headquartered in Paterna, Valencia, Spain.
Tracking iPremom
Last checked October 18, 2026Get iPremom roles before they're posted
A role stays uncontested for about four days. Here's the window, and where we put you in it.
- Live
- +2h+2hRole spotted & verified1 applicant
- +4h+4hYou get the alert1 applicant
- Day 3Day 3You've applied~8 applicants
- Day 7+Day 7+Hits the job boards250+ applicants
Related
More AI companies hiring
Other startups we track in the same space.